U.S. markets open in 7 hours 17 minutes
  • S&P Futures

    3,937.75
    +1.00 (+0.03%)
     
  • Dow Futures

    33,640.00
    +15.00 (+0.04%)
     
  • Nasdaq Futures

    11,507.50
    -2.00 (-0.02%)
     
  • Russell 2000 Futures

    1,809.80
    +1.80 (+0.10%)
     
  • Crude Oil

    72.97
    +0.96 (+1.33%)
     
  • Gold

    1,797.30
    -0.70 (-0.04%)
     
  • Silver

    22.90
    -0.03 (-0.12%)
     
  • EUR/USD

    1.0514
    0.0000 (-0.00%)
     
  • 10-Yr Bond

    3.4080
    0.0000 (0.00%)
     
  • Vix

    22.68
    +0.51 (+2.30%)
     
  • GBP/USD

    1.2201
    -0.0004 (-0.03%)
     
  • USD/JPY

    136.7870
    +0.2630 (+0.19%)
     
  • BTC-USD

    16,824.78
    -115.30 (-0.68%)
     
  • CMC Crypto 200

    394.98
    -7.05 (-1.75%)
     
  • FTSE 100

    7,489.19
    -32.20 (-0.43%)
     
  • Nikkei 225

    27,574.43
    -111.97 (-0.40%)
     

Aptorum Highlights Updates On Clinical Validation of RPIDD Infectious Disease Molecular Diagnostics

  • Aptorum Group Limited (NASDAQ: APMannounced further updates on the analytical, retrospective, and prospective clinical validation of the RPIDD technology in patient samples employed under Illumina iSeq 100 and MiniSeq sequencing platforms.

  • RPIDD, using its proprietary developed depletion and enrichment technologies, has been clinically validated in over 100 patient samples.

  • In the completed retrospective clinical validation, both iSeq 100 and MiniSeq employing the RPIDD workflow demonstrated 100% agreement with positive clinical data in identifying the causative pathogen.

  • In addition, under both iSeq 100 and MiniSeq platforms, RPIDD showed 100% agreement with the negative clinical molecular diagnosis data on the relevant clinical samples.

  • Separately, Aptorum announced the commercial launch of NativusWell in Hong Kong, a new dietary supplement supporting women's health throughout the Menopausal period.

  • NativusWell contains a novel, non-hormonal bioactive ingredient, DOI, designed to support the overall health of women undergoing perimenopause, menopause, and postmenopause.

  • Registration and distribution of NativusWell in the U.S., EU, the U.K., and China are being progressed in parallel as part of Nativus' ongoing global commercialization efforts.

  • Price Action: APM shares are up 4.83% at $1.52 on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.